Hiranita T, Li S, Katz J
J Pharmacol Exp Ther. 2024; 391(2):308-316.
PMID: 39179413
PMC: 11493437.
DOI: 10.1124/jpet.124.002239.
Maremmani I, Dematteis M, Gorzelanczyk E, Mugelli A, Walcher S, Torrens M
J Clin Med. 2023; 12(17).
PMID: 37685642
PMC: 10488107.
DOI: 10.3390/jcm12175575.
Nehlin C, Backstrom J, Brander C, Oster C
Subst Abuse. 2022; 16:11782218221107021.
PMID: 35754979
PMC: 9218892.
DOI: 10.1177/11782218221107021.
Ghanbari R, Li Y, Pathmasiri W, McRitchie S, Etemadi A, Pollock J
Transl Psychiatry. 2021; 11(1):103.
PMID: 33542199
PMC: 7862627.
DOI: 10.1038/s41398-021-01228-7.
Bartoszko A
Nordisk Alkohol Nark. 2020; 36(3):267-285.
PMID: 32934564
PMC: 7434164.
DOI: 10.1177/1455072518814313.
Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health.
Lovrecic B, Lovrecic M, Gabrovec B, Carli M, Pacini M, Maremmani A
Int J Environ Res Public Health. 2019; 16(2).
PMID: 30634521
PMC: 6352208.
DOI: 10.3390/ijerph16020177.
Dopamine Transporter Dynamics of -Substituted Benztropine Analogs with Atypical Behavioral Effects.
Hong W, Wasko M, Wilkinson D, Hiranita T, Li L, Hayashi S
J Pharmacol Exp Ther. 2018; 366(3):527-540.
PMID: 29945932
PMC: 6102189.
DOI: 10.1124/jpet.118.250498.
People Control Their Addictions: No matter how much the "chronic" brain disease model of addiction indicates otherwise, we know that people can quit addictions - with special reference to harm reduction and mindfulness.
Peele S
Addict Behav Rep. 2018; 4:97-101.
PMID: 29511729
PMC: 5836519.
DOI: 10.1016/j.abrep.2016.05.003.
Oxford House Residents' Attitudes Toward Medication Assisted Treatment Use in Fellow Residents.
Majer J, Beasley C, Stecker E, Bobak T, Norris J, Nguyen H
Community Ment Health J. 2018; 54(5):571-577.
PMID: 29302767
DOI: 10.1007/s10597-017-0218-4.
The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment.
Bizzarri J, Casetti V, Sanna L, Maremmani A, Rovai L, Bacciardi S
Ann Gen Psychiatry. 2016; 15:34.
PMID: 27933094
PMC: 5124303.
DOI: 10.1186/s12991-016-0109-z.
Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.
BMC Fam Pract. 2016; 17:24.
PMID: 26931763
PMC: 4774159.
DOI: 10.1186/s12875-016-0413-3.
The Impact of Opioids on Cardiac Electrophysiology.
Wedam E, Haigney M
Curr Cardiol Rev. 2016; 12(1):27-36.
PMID: 26818485
PMC: 4807715.
DOI: 10.2174/1573403x1201160126122405.
An Examination of Women Ex-Offenders With Methadone Histories.
Majer J, Harris J, Jason L
Int J Offender Ther Comp Criminol. 2015; 61(6):711-723.
PMID: 26275413
PMC: 5553198.
DOI: 10.1177/0306624X15600834.
Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.
Monico L, Gryczynski J, Mitchell S, Schwartz R, OGrady K, Jaffe J
J Subst Abuse Treat. 2015; 57:89-95.
PMID: 25986647
PMC: 4560966.
DOI: 10.1016/j.jsat.2015.05.005.
Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.
Mauger S, Fraser R, Gill K
Neuropsychiatr Dis Treat. 2014; 10:587-98.
PMID: 24741316
PMC: 3984058.
DOI: 10.2147/NDT.S39692.
A Users' Guide to 'Juice Bars' and 'Liquid Handcuffs': Fluid Negotiations of Subjectivity, Space and the Substance of Methadone Treatment.
Smith C
Space Cult. 2013; 14(3).
PMID: 24244102
PMC: 3826978.
DOI: 10.1177/1206331211412238.
Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats.
Hiranita T, Kohut S, Soto P, Tanda G, Kopajtic T, Katz J
J Pharmacol Exp Ther. 2013; 348(1):174-91.
PMID: 24194527
PMC: 3868882.
DOI: 10.1124/jpet.113.208264.
Federalizing medical campaigns against alcoholism and drug abuse.
Metlay G
Milbank Q. 2013; 91(1):123-62.
PMID: 23488713
PMC: 3607128.
DOI: 10.1111/milq.12004.
Update on the clinical use of buprenorphine: in opioid-related disorders.
Ducharme S, Fraser R, Gill K
Can Fam Physician. 2012; 58(1):37-41.
PMID: 22267618
PMC: 3264008.
HURRICANE CHANGES: EXAMINING ENHANCED MOTIVATION TO CHANGE DRUG USING BEHAVIORS AMONG KATRINA EVACUEES.
Tiburcio N, Twiggs R, Dunlap E
Anu Investig Adicciones. 2011; 10(1):79-95.
PMID: 21852981
PMC: 3156670.
